Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Common Equity (2016 - 2026)

Usana Health Sciences has reported Common Equity over the past 17 years, most recently at $543.6 million for Q2 2026.

  • Quarterly Common Equity rose 2.6% to $543.6 million in Q2 2026 from the year-ago period, while the trailing twelve-month figure was $543.6 million through Apr 2026, up 2.6% year-over-year, with the annual reading at $533.1 million for FY2026, 0.19% changed from the prior year.
  • Common Equity was $543.6 million for Q2 2026 at Usana Health Sciences, up from $533.1 million in the prior quarter.
  • Over five years, Common Equity peaked at $543.6 million in Q2 2026 and troughed at $389.9 million in Q2 2022.
  • The 5-year median for Common Equity is $498.6 million (2023), against an average of $481.6 million.
  • Year-over-year, Common Equity decreased 10.53% in 2022 and then increased 16.77% in 2023.
  • A 5-year view of Common Equity shows it stood at $434.5 million in 2022, then grew by 14.44% to $497.2 million in 2023, then increased by 7.02% to $532.1 million in 2024, then dropped by 0.76% to $528.1 million in 2025, then grew by 2.93% to $543.6 million in 2026.
  • Per Business Quant, the three most recent readings for USNA's Common Equity are $543.6 million (Q2 2026), $533.1 million (Q1 2026), and $528.1 million (Q3 2025).